Evidence map›Paper›PMID 41030988›Full record

ArticlebioRxiv : the preprint server for biology2025

SMARCA4 is essential for early-stage tumor development but its loss promotes late-stage cancer progression in small-cell lung cancer.

Nicole A Kirk, Jin Ng, Kate-Lin Ly, Young Ho Ban, Godfrey Dzhivhuho, Jinho Jang, Kyung-Pil Ko, Michael S Kareta, Jae-Il Park, Anthony N Karnezis and 3 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Nicole A KirkDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia, USA.
Jin NgACRF Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria, Australia.
Kate-Lin LyDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia, USA.
Young Ho BanDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia, USA.
Godfrey DzhivhuhoDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia, USA.
Jinho JangDepartment of Experimental Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Kyung-Pil KoDepartment of Experimental Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Michael S KaretaCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, South Dakota, USA.
Jae-Il ParkDepartment of Experimental Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-0737-2654
Anthony N KarnezisDepartment of Pathology and Laboratory Medicine, University of California Davis, Sacramento, California, USA.
Anish ThomasDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Kate D SutherlandACRF Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria, Australia.ORCID 0000-0002-7453-3366
Kwon-Sik ParkDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia, USA.ORCID 0000-0003-3346-9086

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1M
Targeting BCAT1 and branched-chain amino acid metabolism for the detection and prevention of SCLCU01CA224293 · NCI · UNIVERSITY OF VIRGINIA · PI PARK, KWON-SIK · 2018 to 2022
$2.2M
CRACD-controlled cell plasticity and small cell lung cancerR01CA278967 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Jae-Il Park, Kwon-Sik Park · 2024 to 2026
$1.8M
NCI NIH HHS P30 CA044579NCI NIH HHS R01 CA278967NCI NIH HHS U01 CA224293
6 · The paper itself

Abstract

SMARCA4 and other components of the SWI/SNF chromatin remodeling complex have been implicated in various cancers. Yet, its role in small cell lung cancer (SCLC) tumorigenesis remains poorly understood. Genetically engineered mouse models (GEMMs) of SCLC revealed that deletion of

Indexed as

NE differentiationSCLCSMARCA4

Identifiers

PMID41030988
PMCPMC12478319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.